The material is researched within the patent literature for its anxiolytic properties and reduced sedative, hypnotic, and ataxic side-effects, but it doesn't appear to be licensed for healthcare use. Łukasik-Głebocka et al Withdrawal symptoms or rebound indications could arise just after ceasing use abruptly following a handful of weeks https://reidqagnu.59bloggers.com/36692385/flubromazolam-vs-bromazolam-for-dummies